The Cooper Companies, Inc. Common Stock
COOThe Cooper Companies, Inc. (COO) is a global medical device company that specializes in designing, manufacturing, and marketing healthcare products, primarily in the fields of vision correction and women's health. The company's vision segment offers contact lenses and related products, including brands like CooperVision, while its women’s health segment develops and distributes medical devices for the treatment of gynecological conditions. Founded in 1979 and headquartered in Pleasanton, California, Cooper Companies is known for its innovation and focus on patient healthcare solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 11, 2023 | $0.03 | 2023-07-26 | 2023-07-27 |
| February 10, 2023 | $0.03 | 2023-01-20 | 2023-01-23 |
| August 11, 2022 | $0.03 | 2022-07-26 | 2022-07-27 |
| February 9, 2022 | $0.03 | 2022-01-20 | 2022-01-21 |
| August 11, 2021 | $0.03 | 2021-07-26 | 2021-07-27 |
Dividends Summary
- Consistent Payer: The Cooper Companies, Inc. Common Stock has rewarded shareholders with 40 dividend payments over the past 19 years.
- Total Returned Value: Investors who held COO shares during this period received a total of $1.20 per share in dividend income.
- Latest Payout: The most recent dividend of $0.03/share was paid 1072 days ago, on August 11, 2023.
- Dividend Growth: Since 2004, the dividend payout has grown by 0.0%, from $0.03 to $0.03.
- Dividend Reliability: COO has maintained or increased its dividend for 40 consecutive payments.
Company News
As the stock market rotates away from mega-cap tech, three undervalued stocks offer compelling opportunities: Keurig Dr Pepper trades at a discount to beverage peers with attractive dividend yield; Cooper Companies benefits from healthcare sector resilience with strong EPS growth prospects; and Matador Resources capitalizes on the energy sector's...
The global ART market is projected to grow from $30.1 billion in 2024 to $60.7 billion by 2033 at a CAGR of 8.1%, driven by rising infertility prevalence, delayed parenthood, and expanding employer-sponsored fertility benefits. IVF dominates with 90% market share, while Europe leads with 35.80% of the global market. Over 450 Fortune 500 companies...
The global ART market is projected to grow from $30.1 billion in 2024 to $60.7 billion by 2033 at a CAGR of 8.1%, driven by rising infertility prevalence, delayed parenthood, and expanding employer-sponsored fertility benefits. IVF dominates with 90% market share, while Europe leads with 35.80% of the global market. Over 450 Fortune 500 companies...
The global contact lens market is projected to grow from USD 18.88 billion in 2025 to USD 26.64 billion by 2033, expanding at a CAGR of 4.42%. Growth is driven by rising myopia prevalence, increasing adoption of disposable lenses, and technological advancements in silicone hydrogel materials. However, risks from eye infections and user discomfort...
A Georgia federal judge denied Teva Pharmaceutical's request to delay the first trial in approximately 3,800 lawsuits alleging its Paragard copper IUD can fracture during removal. The trial is scheduled to proceed on January 20. The judge previously expressed concerns about Teva's five-year delay in complying with an FDA mandate to update warning...
